Oncothyreon pursues strategic alliances to expedite development of products based on the Company's fundamental technologies. Oncothyreon evaluates collaboration, in-licensing and out-licensing opportunities that have the potential to complement the company's strengths and move product candidates through to commercialization.
- Small Molecules - Oncothyreon expects to partner its small molecule candidates for late stage clinical development and marketing
- Adjuvant Partnering - Oncothyreon has acquired or developed vaccine technologies that are available for license. This includes the fully synthetic toll-like receptor 4 agonist pet lipid-A.
Click here for a non-confidential description of PX-866
Synthetic Lipid A Analogs
Pet lipid-A is widely known as a toll like receptor 4 (TLR4) agonist. Our synthetic lipid analogs are easy to formulate with vaccines and provide strong innate immune stimulation. Pet lipid-A has been manufactured under cGMP as an adjuvant for vaccine formulations for clinical trials.
- Zi-Hua Jiang et al, pet lipid-A structures containing novel lipid moieties: Synthesis and adjuvant properties, Bioorganic and Medicinal Chemistry Letters, 12, 2193-2196 (2002)
- Zi-Hua Jiang et al, Novel lipid-A mimetics derived from pentaerythritol: Synthesis and their potential agonistic activity. Tetrahedron, 58, 8833-8842 (2002)
- Zi-Hua Jiang and R. Rao Koganty, Synthetic Vaccines: The Role of Adjuvants in Immune Targeting. Current Medicinal Chemistry 10, 1423-1439 (2003)
- R. Rao Koganty, Vaccines, exploiting the roll of toll-like receptors (Editorial). Expert Review of Vaccines 1, 123,-124 (2002)
- R. Rao Koganty, Vaccine safety: a case for synthetic vaccine formulations (Editorial), Expert Review of Vaccines 2, 275-727 (2003)
For more information on business development opportunities at Oncothyreon, contact
Guy Cipriani, email email@example.com
return to top ^